The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Janux Therapeutics Inc shares valued at $1,005,000 were sold by Campbell David Alan on Dec 03 ’24. At $67.00 per share, Campbell David Alan sold 15,000 shares. The insider’s holdings dropped to 242,054 shares worth approximately $16.05 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Campbell David Alan sold 25,000 shares, netting a total of over 1,289,879 in proceeds. Following the sale of shares at $51.60 each, the insider now holds 257,054 shares.
Before that, Reardon Tighe had added 5,202 shares to its account. In a trade valued at $277,987, the FORMER OFFICER bought Janux Therapeutics Inc shares for $53.44 each.
As published in a research note from H.C. Wainwright on December 03, 2024, Janux Therapeutics Inc [JANX] has been retained to a Buy and the price target has been revised to $70. Analysts at BTIG Research resumed the stock at ‘”a Buy”‘ outlook in a report released in early December. As of November 22, 2024, Leerink Partners has initiated its “an Outperform” rating for JANX. Earlier on October 24, 2024, UBS initiated its rating. Their recommendation was “a Buy” for JANX stock.
Analyzing JANX Stock Performance
During the last five days, there has been a surge of approximately 42.92%. Over the course of the year, Janux Therapeutics Inc shares have jumped approximately 517.89%. Shares of the company reached a 52-week high of $71.71 on 12/05/24 and a 52-week low of $7.79 on 02/05/24. A 50-day SMA is recorded $50.61, while a 200-day SMA reached $45.63. Nevertheless, trading volume fell to 3.85 million shares from 0.46 million shares the previous day.
Support And Resistance Levels for Janux Therapeutics Inc (JANX)
According to the 24-hour chart, there is a support level at 63.54, which, if violated, would cause prices to drop to 60.79. In the upper region, resistance lies at 70.38. The next price resistance is at 74.47. RSI (Relative Strength Index) is 68.54 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 13.38, which suggests the price will increase in the coming days. Percent R is at 17.07%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
